Heartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation

Reuters01-12

Heartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation

Heartflow Inc. has released an investor presentation outlining the company's leadership in AI technology for coronary artery disease (CAD). The presentation highlights Heartflow's growth in the U.S. market, reporting an increase in active physician customers and improvements in non-GAAP gross margin over the past year. Heartflow's platform is described as clinically proven to support the detection, diagnosis, management, and treatment of CAD, with a current focus on symptomatic patients and a mid-term strategy to expand into targeted asymptomatic markets. The company reports that its test volumes as a percentage of total non-invasive tests for CAD in the U.S. have increased annually from 2020 to 2025. Future growth drivers include expanding the U.S. addressable market and further development of the Heartflow platform, including new products for plaque analysis and disease staging. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602543509?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602543509","market":"fut","top_or_hot":-1,"title":"Heartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heartflow Inc. has released an investor presentation outlining the company's leadership in AI technology for coronary artery disease (CAD). The presentation highlights Heartflow's growth in the U.S. market, reporting an increase in active physician customers and improvements in non-GAAP gross margin over the past year. Heartflow's platform is described as clinically proven to support the detection, diagnosis, management, and treatment of CAD, with a current focus on symptomatic patients and a mid-term strategy to expand into targeted asymptomatic markets. The company reports that its test volumes as a percentage of total non-invasive tests for CAD in the U.S. have increased annually from 2020 to 2025. Future growth drivers include expanding the U.S. addressable market and further development of the Heartflow platform, including new products for plaque analysis and disease staging. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heartflow Inc. has released an investor presentation outlining the company's leadership in AI technology for coronary artery disease (CAD). The presentation highlights Heartflow's growth in the U.S. market, reporting an increase in active physician customers and improvements in non-GAAP gross margin over the past year. Heartflow's platform is described as clinically proven to support the detection, diagnosis, management, and treatment of CAD, with a current focus on symptomatic patients and a mid-term strategy to expand into targeted asymptomatic markets. The company reports that its test volumes as a percentage of total non-invasive tests for CAD in the U.S. have increased annually from 2020 to 2025. Future growth drivers include expanding the U.S. addressable market and further development of the Heartflow platform, including new products for plaque analysis and disease staging. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL2ngHK9:1","article_id":"2602543509","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602543509","pubTimestamp":1768225810,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Heartflow Inc. has released an investor presentation outlining the company's leadership in AI technology for coronary artery disease . The presentation highlights Heartflow's growth in the U.S. market, reporting an increase in active physician customers and improvements in non-GAAP gross margin over the past year. Heartflow's platform is described as clinically proven to support the detection, diagnosis, management, and treatment of CAD, with a current focus on symptomatic patients and a mid-term strategy to expand into targeted asymptomatic markets. The company reports that its test volumes as a percentage of total non-invasive tests for CAD in the U.S. have increased annually from 2020 to 2025. Future growth drivers include expanding the U.S. addressable market and further development of the Heartflow platform, including new products for plaque analysis and disease staging. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","HTFL":"HeartFlow Inc"},"translate_title":"Heartflow Inc.在新的投资者演示中展示了人工智能驱动的CAD护理进步和增长战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HTFL":0.9},"content_text":"Heartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation\n    \n\n        Heartflow Inc. has released an investor presentation outlining the company's leadership in AI technology for coronary artery disease (CAD). The presentation highlights Heartflow's growth in the U.S. market, reporting an increase in active physician customers and improvements in non-GAAP gross margin over the past year. Heartflow's platform is described as clinically proven to support the detection, diagnosis, management, and treatment of CAD, with a current focus on symptomatic patients and a mid-term strategy to expand into targeted asymptomatic markets. The company reports that its test volumes as a percentage of total non-invasive tests for CAD in the U.S. have increased annually from 2020 to 2025. Future growth drivers include expanding the U.S. addressable market and further development of the Heartflow platform, including new products for plaque analysis and disease staging. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602543509","isCrawlerRequest":true}